# Kreske Nickelsen

> Kreske Nickelsen is a Series A investor at kineo finance backing Health Care. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [kineo finance](https://shizune.co/investors/profile/diamedcare)
- Location: Warsaw, Poland
- Total investments: 7
- Last investment: Sep 2023
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: http://in.linkedin.com/pub/kreske-nickelsen/10/30b/324

Kreske Nickelsen is a Series A investor at kineo finance in Warsaw focused on Health Care and Apps. Kreske Nickelsen is a venture capital professional with more than 18 years of supervisory board and investment experience in companies based all over Europe. Before JPIF, she was a partner at Aescap, a life science venture capital fund based in Amsterdam (www.Aescap.com), and before that a director at 3i Group plc in London (www.3igroup.com). Sheholds an MBA from INSEAD (France) and a Masters in Biology from Philipps University Marburg (Germany).

## Contacts

5 contacts available for Kreske Nickelsen: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/kreske-nickelsen?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Apps | 2 | 29% |
| Hospital | 1 | 14% |
| Biotechnology | 1 | 14% |
| Public Safety | 1 | 14% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 57% |
| Seed | 1 | 14% |
| Series B | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Poland | 1 | 14% |
| Austria | 1 | 14% |
| Germany | 1 | 14% |
| United States | 1 | 14% |
| The Netherlands | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Microsure | Microsurgery is characterized by performing surgery close to the limits of what is physically possible. It has designed a motion stabilizer system, which is designed by and for microsurgeons who want to overcome their physical limitations and enhance their performance. The Microsure motion stabilizer system has improved the quality of microsurgicalprocedures and makes it easier to perform, with the objective to increase the number of treatment options for patients.The extraordinary control and precision offered by the Microsure motion stabilizer provides better and more constant surgical outcome and allows the development of new highly accurate surgical procedures that are currently unavailable. The Microsure system has already been successfully used in a first clinical trial with 8 micro-surgical operations for lymphedema in the Maastricht UMC+. With our investment, Microsure will accelerate the market introduction and sales of its systems.Microsure was founded in 2014 and is headquartered in Eindhoven, The Netherlands. | $40.6M | Series B | Sep 19, 2023 |  |
| Grand perspective | Grand perspective provides early warning solution for hazardous gases that covers complete industrial sites. | $6.9M | Series A | Oct 17, 2022 |  |
| DreamJay | We’re a team of scientists, designers and entrepreneurs working on digital solutions to empower people to sleep and dream better. After 3 years of research and experiments in a sleep lab as well as cooperation with sleep medicine experts, neuropsychologists, audiovisual researchers, we've found a way to improve sleep quality with activesleep stimulation. To make it accessible to the wide public we've developed the Nightly app - the world’s first app that actively stimulates you during sleep to make your sleep more efficient resulting in happier and healthier you. Nightly helps you fall asleep easily, reduces bad dreams & the number of awakenings during the night and also helps you get up by waking you up in the lightest sleep stage. Find out more at www.nightlyapp.co | $2.3M | Series A | Sep 15, 2017 |  |
| Nightly | Nightly helps you enjoy healthy sleep. It actively works to keep your night restful in three ways: it helps you easily fall asleep, limit bad dreams and reduce the likelihood of nighttime awakenings. This innovative, scientifically-developed technology is a combination of two factors: audio-visual stimuli and advanced AI algorithms.Nightlymonitors your sleep live, recognizes critical moments during your night and reacts with soothing sounds to help you minimize the possibility of a wakeup. It stimulates your sleep to help you keep your rest uninterrupted. | $2.3M | Series A | Sep 15, 2017 |  |
| ProtAffin Biotechnologie | ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions ofspecific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform. | $1.5M | Series A | Jan 21, 2008 |  |
| ProtAffin Biotechnologie | ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions ofspecific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform. | $2.9M | Series A | May 04, 2007 |  |
| Sound Object Technologies | Sound Object Technologies is develops technology for obtaining and processing information from sound signals for application in medical devices. |  | Seed |  |  |

7 of 7 investments shown.

## Co-investors
- [Nordic Makers](https://shizune.co/investors/profile/nordic-makers-vc) — VC Fund, 2 deals together
- [Brandenburg Kapital](https://shizune.co/investors/profile/bfb-brandenburg-kapital-gmbh) — VC Fund, 1 deal together
- [BOM Brabant Ventures](https://shizune.co/investors/profile/bom-brabant-ventures) — VC Fund, 1 deal together
- Eindhoven University of Technology — VC Fund, 1 deal together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 1 deal together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 1 deal together

## About kineo finance

VC Fund · Basel, Switzerland

kineo finance is a globally active financing specialist for innovative technologies and equipment. Originally under the name of DiaMedCare, kineo provides tailor-made venture leasing and working capital solutions for companies which are starting the commercialisation of new products and services with a hardware component. kineo enables youngcompanies to offer their customers product/market-specific "equipment-as-a-service" solutions via pay-per-use, renting or subscription models. Backed by large institutional investors, kineo offers a broad industry network and know-how and actively supports high-growth companies to accelerate the market entry of their innovations.

3 contacts available at kineo finance.

| Name | Title | Profile |
| --- | --- | --- |
| Gerhard Ries | Founder & CEO | https://shizune.co/investors/profile/gerhard-ries |
| Kreske Nickelsen | Partner | — |
| Christine Müller | Partner | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kreske Nickelsen invest in?

Kreske Nickelsen invests primarily in Health Care, Apps and Hospital startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in Poland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kreske Nickelsen?

Public channels for Kreske Nickelsen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Kreske Nickelsen last invest?

The most recent investment recorded for Kreske Nickelsen closed in Sep 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co